Lyell Immunopharma Announces Participation in March Investor Conferences
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data [Seeking Alpha]
Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain [Yahoo! Finance]
Lyell Immunopharma (NASDAQ:LYEL) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.